Enlight Medical is developing invasive and non-invasive BCIs to help replace, restore, or improve human functions.
Enlight Medical has partnered with Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, to accelerates commercial availability of Seer’s Proteograph Product Suite to the rapidly expanding Chinese life sciences and clinical markets.
Enlight Medical was founded in Boston, Massachusetts, the United States. It is a stable and rapidly growing global medical technology company, focusing on interventional medical devices for structural heart diseases and intravascular diseases, as well as neuromodulation products. The company has established R&D centers or production bases in Boston, San Francisco, Shanghai, Beijing and Shenzhen, and all of its production workshops comply with GMP standards.
2021年11月3日，應脈醫療科技（上海）有限公司的NovoClasp?經導管二尖瓣夾及可操控導引導管系統在首都醫科大學附屬北京安貞醫院完成首例人體植入。本例手術由首都醫科大學附屬北京安貞醫院院長張宏家教授、中國醫學科學院阜外醫院吳永健教授現場指導，首都醫科大學附屬北京安貞醫院心臟瓣膜病介入中心宋光遠教授團隊、超聲科何怡華教授團隊完成，香港亞洲心臟中心林逸賢教授提供遠程輔助，為一位高齡重度二尖瓣反流的患者成功實施微創介入二尖瓣緣對緣修復手術。本例手術的成功標志著NovoClasp?二尖瓣修復系統順利開展首次人體臨床研究入組。
2021年10月18日，應脈醫療宣布完成數億人民幣B輪融資，本輪融資由國投招商、海松資本及前海母基金共同領投，楹聯健康基金跟投，原股東高瓴創投、惠每資本、真格基金、辰德資本繼續增持。
2021年9月13日~9月17日，中國結構周國際頻道特別推出“Device To World中國器械走向世界——創新論壇圓桌會”。作為中國結構周首個醫械國際交流論壇，通過圓桌討論的形式，讓全球的專家學者認識和了解中國原創器械的風采與優勢。會上，NovoClasp?二尖瓣系統作為本場首發國產器械驚艷亮相，受到了國內外專家的關注與褒贊。
@Copyright 2020-2022 Enlight Medical Limited All rights reserved 滬ICP備20012889號-2
